Products with Inhibitors bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5773 | Boehmenan |
| 1. Boehmenan exhibits cytotoxicity against both Wnt-dependent (HCT116) and Wnt-independent (RKO) cells, it decreases the expression of full, cytosolic and nuclear β-catenin along with c-myc in STF/293 cells, suggestes that boehmenan may have inhibited the Wnt signal by decreasing β-catenin levels. 2. (±)-Boehmenan shows potent protein-tyrosine phosphatase 1B (PTP1B) inhibitory activity in vitro with the IC(50) values of 43.5 um, it inhibits PTP1B activity in a competitive manner. 3. Boehmenan exhibits the potent cytotoxic effects against many cancer cell lines, boehmenan-mediated anti-tumor property is mediated by modulation of mitochondria and EGFR signaling pathway in A549 NSCLC cells. | |
| BCN5782 | (3beta,24xi)-Cycloartane-3,24,25-triol |
| 1. Cycloartane-3,24,25-triol has potential for development as an anti-cancer agent against prostate cancer. 2. Cycloartane-3,24,25-triol reduces the viability of PC-3 and DU145 cell lines with IC50 values of 2.226 ± 0.28 μM and 1.67 ± 0.18 μM respectively. | |
| BCN5790 | Aurantiamide |
| 1. Aurantiamide acetate may suppress the growth of malignant gliomas by blocking autophagic flux. 2. Aurantiamide acetate has an anti-neuroinflammatory effect on LPS stimulation through its inhibition of the NF-κB, JNK and p38 pathways. 3. Aurantiamide acetate inhibits cysteine proteinases, in particular, cathepsin L (3.4.22.15) and B (3.4.22.1) with IC50 of 12 microM and 49 microM, respectively . 4. Aurantiamide acetate is the main active substance of EECTD, which has significant anti-inflammatory and antinociceptive activities. | |
| BCN5794 | Gomisin A |
| Gomisin A has anti-inflammatory, antihypertensive, neuroprotective, and anti-proliferation properties, it induces marked protective effects against hepatic and renal injury induced by CCl(4) exposure through differential regulation of the MAPK signal transduction pathway. Gomisin A inhibits COX-2, iNOS, IL-6, TNF-α and NO through the down-regulation of RIP2 and NF-κB activation. | |
| BCN5815 | Schisandrin A |
| Schisandrol A may be a new promising treatment for neurotoxicity, erectile dysfunction and cardiovascular disease.It can inhibit the activities of Pgp,Beta Amyloid,CYP3A4,cGMP,and NOS, the IC(50) value of CYP3A4 is 32.02 microM. | |
